Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome.
Giannoccaro, Maria Pia, Cossins, Judith, Sørland, Kari et al. · Clinical therapeutics · 2019 · DOI
Quick Summary
Researchers tested blood samples from 50 ME/CFS patients and 50 healthy people to see if ME/CFS patients had unusual antibodies (immune proteins) that attack nerve cells. While a small number of both patients and healthy people had some immune activity toward nerve proteins, only one ME/CFS patient had a specific antibody that could be clearly identified. Interestingly, the patients who did have these antibodies tended to have more severe symptoms and had become ill more recently.
Why It Matters
Understanding whether autoantibodies play a role in ME/CFS could lead to new diagnostic tools and treatments targeting the immune system. This study provides foundational evidence that while autoantibodies are not a universal feature of ME/CFS, they may be important in a subset of patients, particularly early in disease, warranting further investigation.
Observed Findings
Only 1 ME/CFS patient had specific, clearly identifiable serum antibodies (vs. 2 healthy controls)
8 patients (16%) showed some immunoreactivity to neuronal proteins compared to 11 controls (22%)
Patients with seropositive status had shorter disease duration at the time of study
Patients with seropositive status reported more severe symptoms
No single antibody was identified that appeared specific to or causative in ME/CFS
Inferred Conclusions
Neuronal autoantibodies are not a universal or characteristic feature of ME/CFS
Antibodies may play a role specifically in early-stage disease or in a disease subset
Future studies should focus on longitudinal antibody tracking from disease onset
Remaining Questions
Do antibodies appear at disease onset and diminish over time, or do they persist in certain patients?
What triggers autoantibody production in the subset of patients who develop them?
What This Study Does Not Prove
This study does not prove that antibodies cause ME/CFS symptoms or that autoimmunity is the primary mechanism in ME/CFS. The association between antibodies and severity does not establish causation—antibodies could be a consequence rather than a cause of illness. The rarity of specific antibodies means they cannot be used as a diagnostic marker for most ME/CFS patients.